FI120687B - Substituerade 2-(2,6-dioxopiperidin-3-yl) ftalimider och -1-oxoisoindoliner samt förfarande för sänkande av TNFalfa nivåerna - Google Patents
Substituerade 2-(2,6-dioxopiperidin-3-yl) ftalimider och -1-oxoisoindoliner samt förfarande för sänkande av TNFalfa nivåerna Download PDFInfo
- Publication number
- FI120687B FI120687B FI990101A FI990101A FI120687B FI 120687 B FI120687 B FI 120687B FI 990101 A FI990101 A FI 990101A FI 990101 A FI990101 A FI 990101A FI 120687 B FI120687 B FI 120687B
- Authority
- FI
- Finland
- Prior art keywords
- oxo
- dioxopiperidin
- hydrogen
- compound
- aminoisoindoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (42)
1. En förening som har följande formel eller dess sait: R4 U 5 väri: den ena av X och Y är C=0 och den andra av X och Y är C=0 eller CH2; (i) var och en av R1, R2, R3 och R4 oberoende av varandra är en halogen-, alkyl- med 1-4 kolato-10 mer, eller en alkoxigrupp med 1-4 kolatomer, eller (ii) nägon av R1, R2, R3 och R4 är en -NHR5-grupp och de kvarvarande R1, R2, R3 och R4 är väte; R5 är väte eller en alkylgrupp med 1-8 kolatomer;
2. Förening enligt patentkrav 1, väri var och • · ... en av R1, R2, R3 och R4 oberoende av varandra är en ha- • · logengrupp, en alkylgrupp med 1-4 kolatomer, eller • · · en alkoxigrupp med 1-4 kolatomer, och R6 är en • · · *·* ’ 25 metyl-, etyl-, propyl- eller bensylgrupp.
3. Förening enligt patentkrav 1, väri nägon ’· av R1, R2, R3 och R4 är en -NH2-grupp, de kvarvarande :***: R1, R2, R3 och R4 är väte, och R6 är en metyl-, etyl-, • · · propyl- eller bensylgrupp. . 30
4. Förening enligt patentkrav 1, väri den ena av X och Y är C=0 och den andra av X och Y är CH2. : 5. Förening enligt patentkrav 1, väri den ena • · · av X och Y är C=0 och den andra av X och Y är CH2; • · · nägon av R1, R2, R3 och R4 är en -NH2-grupp, de kvarvarande R1, R2, R3 och R4 är väte; och R6 är vä-te.
5 CH2; nagon av R1, R2, R3 och R4 är en -NH2-grupp och de kvarvarande R1, R2, R3 och R4 är väte; och R6 är väte.
6. Förening enligt patentkrav 1, vilken är 1-5 oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin.
7. Förening enligt patentkrav 1, vilken är 1-oxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindolin, 1-oxo-2-(2,6-dioxopiperidin-3-yl)-6-aminoisoindolin, 1-oxo-2-(2,6-dioxopiperidin-3-yl)-7-aminoisoindolin, Ι- ΙΟ oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7-tetrafluoriso-indolin, l-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7- tetraklorisoindolin, l-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6,7-tetrametylisoindolin, l-oxo-2-(2,6-dioxo-piperidin-3-yl)-4,5,6,7-tetrametoxiisoindolin, 3- (1- 15 oxo-4—aminoisoindolin-l-yl)-3-metylpiperidin-2,6-dion, 3-(l-oxo-4—aminoisoindolin-l-yl)-3-etylpiperidin-2,6-dion, 3-(l-oxo-4—aminoisoindolin-l-yl)-3-propylpiperi-din-2,6-dion eller 3-(3-aminoftaliimido)-3-metyl-piperidin-2,6-dion.
8. En optisk isomer av en förening som har följande formel eller dess sait: • • · · · · • · *...* r6 f? ::::! • · · • · · • · · • (1) • · · • · · • · · väri: 25 den ena av X och Y är C=0 och den andra av X • ·· *·* * och Y är C=0 eller CH2; • · · ·...· (i) var och en av R1, R2, R3 och R4 oberoende av varandra är en halogen-, alkyl-, med 1-4 kolato-mer, eller en alkoxigrupp, med 1-4 kolatomer, eller • · . 30 (ii) nägon av R1, R2, R3 och R4 är en -NHR5-grupp och de kvarvarande R1, R2, R3 och R4 är väte; • ·· • · • « ♦ · ♦ R5 är väte eller en alkylgrupp med 1-8 kolatomer; R6 är väte, en alkyl-, med 1-8 kolatomer, bensyl- eller halogengrupp.
9. En optisk isomer enligt patentkrav 8, vars optiska renhet är > 95 %.
10 NH2-grupp, de kvarvarande R1, R2, R3 och R4 Sr väte; och R6 är väte, en metyl-, etyl-, propyl- eller ben-sylgrupp.
10. En optisk isomer enligt patentkrav 8, väri den ena av X och Y är C=0 och den andra av X och Y är CH2.
11. En optisk isomer enligt patentkrav 8, väri den ena av X och Y är C=0 och den andra av X och Y är CH2; nägon av R1, R2, R3 och R4 är en -NH2-grupp och de kvarvarande R1, R2, R3 och R4 är väte; och R6 är väte, en metyl-, etyl-, propyl-, bensyl- eller halo- 15 gengrupp.
12. Optisk isomer enligt patentkrav 11, väri R6 är väte.
13. Optisk isomer enligt patentkrav 9, vilken är (R)-l-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoin- 20 dolin eller (S)—l-oxo-2-(2,6-dioxopiperidin-3-yl)-4- aminoisoindolin.
14. Optisk isomer enligt patentkrav 9, vilken • · ... är (R)-1, 3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino- **·. isoindolin eller (S)—1,3-dioxo-2-(2,6-dioxopiperidin- 25 3-yl)-4-aminoisoindolin. • · · • · *...* 15. Farmaceutisk sammansättning, vilken om- • · · V : fattar en förening enligt nägot av patentkraven 8 - • · · : : : 14.
15 R5 är väte eller en alkylgrupp med 1-8 kolatomer; R6 är väte, en alkyl-, med 1-8 kolatomer, bensyl- eller halogengrupp; pä det villkor, att R6 är nägot annat än ,···, 20 väte, ifall X och Y är C=0 och (i) var och en av R1, • · R2, R3 och R4 är en halogengrupp, • · ... för att användas vid sänkande av TNFa-niväer • · *···* i däggdjur, förhindrande av angiogenes eller värdande • · · *·* ’ av en inflammatorisk, autoimmun eller neoplastisk • M V · 25 sjukdom.
15 Rs är väte, en alkylgrupp med 1-8 kolato mer, en bensyl- eller halogengrupp; pä det villkor, att R6 är nägot annat än väte, if all X och Y är C=0 och (i) var och en av R1, ·;··· R2, R3 och R4 är en halogengrupp eller (ii) nägon av .···. 2 0 R1, R2, R3 eller R4 en -NH2-grupp. • · ·
16. Farmaceutisk sammansättning enligt pa- .*:*. 30 tentkrav 15, vilken omfattar (R)-l-oxo-2-(2,6- .···. dioxopiperidin-3-yl)-4-aminoisoindolin eller (S)—1- • · ”* oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin, *·”· varvid nämnda (R)-l-oxo-2-(2,6-dioxopiperidin-3-yl)-4- ”**! aminoisoindolins eller (S) —l-oxo-2-(2, 6-dioxopiperi- . 35 din-3-yl)-4-aminoisoindolins optiska renhet är > 95%. • · · I”
17. Farmaceutisk sammansättning enligt pa- *** tentkrav 15, vilken omfattar (R)-1,3-dioxo-2-(2,6- dioxopiperidin-3-yl)-4-aminoisoindolin eller (S) —1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin, varvid nämnda (R)-1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolins eller (S) —1,3-dioxo-2-(2,6- 5 dioxopiperidin-3-yl)-4-aminoisoindolins optiska renhet är > 95%.
18. En farmaceutisk sammansättning, vilken omfattar en förening, som har följande formel, eller dess salt: 10 * vari : den ena av X och Y är C=0 och den andra av X och Y är C=0 eller CH2; (i) var och en av R1, R2, R3 och R4 oberoende 15 av varandra är en halogen-, alkyl-, med 1-4 kolato-mer, eller en alkoxigrupp, med 1-4 kolatomer, eller (ii) nägon av R1, R2, R3 och R4 är en -NHR5-grupp och de kvarvarande R1, R2, R3 och R4 är väte; ·:**: R5 är väte eller en alkylgrupp med 1-8 20 kolatomer; • » ··· c. ....: R är väte, en alkyl-, med 1-8 kolatomer, • · .···. bensyl- eller halogrupp; III pä det villkor, att R är nägot annat än • · · *·* * väte, ifall X och Y är C=0 och (i) var och en av R1, ··· ' ' ' · • · · *·* ' 25 R , R och R är en halogengrupp, och en farmaceutiskt godtagbar bärare, ett • · · ί,ί ! utspädningsmedel eller ett fyllnadsmedel. I l
19. Farmaceutisk sammansättning enligt pa- | . tentkrav 18 för användning vid sänkande av TNFa- • t . 30 niväerna i däggdjur, förhindrande av angiogenes eller vardande av en inflammatorisk, autoimmun eller neo- : plastisk sjukdom. ···
20. Farmaceutisk sammansättning enligt pa- • · · tentkrav 18, vari nämnda sammansättning är i form av en tablett, kapsel, halspastill, liten pase, lösning, suspension, emulsion, ett pulver, en aerosol, injektion, ett suppositorium, en tampong, ett vagitorium, en pastill, salva, kräm, pasta, ett skum, eller gel.
21. Farmaceutisk sammansättning enligt pa tent krav 18, väri den ena av X och Y är C=0 och den andra av X och Y är CH2.
22. Farmaceutisk sammansättning enligt patent krav 18, väri nägon av R1, R2, R3 och R4 är en -
23. Farmaceutisk sammansättning enligt pa- tentkrav 22, väri R6 är väte.
24. Farmaceutisk sammansättning enligt pa- tentkrav 18, väri föreningen är l-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin.
25. Farmaceutisk sammansättning enligt pa- tentkrav 18, väri X och Y är C=0.
26. Farmaceutisk sammansättning enligt pa- tentkrav 18, väri föreningen är 1,3-dioxo-2-(2,6- ...,· dioxopiperidin-3-yl) -4-aminoisoindolin.
• · ... 27. Farmaceutisk sammansättning enligt pa- • · •*\ tentkrav 18, väri föreningen är l-oxo-2-(2,6- 25 dioxopiperidin-3-yl)-5-aminoisoindolin, l-oxo-2-(2,6- • · · • · *...· dioxopiperidin-3-yl)-6-aminoisoindolin, l-oxo-2-(2,6- • · · ·.♦ · dioxopiperidin-3-yl)-7-aminoisoindolin, l,3-dioxo-2- (2, 6-dioxopiperidin-3-yl)-5-aminoisoindolin, 1,3- dioxo-2-(2,6-dioxopiperidin-3-yl)-6-aminoisoindolin, 30 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-7-aminoisoindo- ,···. Iin, l-oxo-2-(2, 6-dioxopiperidin-3-yl)-4,5, 6, 7-tetra- • · *1* f luorisoindolin, l-oxo-2-(2,6-dioxopiperidin-3-yl) - ·*’· 4,5, 6, 7-tetraklorisoindolin, l-oxo-2-(2,6-dioxopiperi- din-3-yl)-4,5,6,7-tetrametylisoindolin, l-oxo-2-(2,6- . 35 dioxopiperidin-3-yl)-4,5, 6, 7-tetrametoxiisoindolin, 3- • · ♦ IV. (l-oxo-4—aminoisoindolin-l-yl) -3-metylpiperidin-2,6- • · *** dion, 3-(l-oxo-4—aminoisoindolin-l-yl)-3-etylpiperi- din-2,6-dion, 3-(l-oxo-4—aminoisoindolin-l-yl)-3-pro- pylpiperidin-2,6-dion eller 3-(3-aminoftalimido)-3-metylpiperidin-2,6-dion.
28. Förening, som har följande formel eller 5 dess salt: R4 vari : den ena av X och Y är C=0 och den andra av X och Y är C=0 eller CH2; 10 (i) var och en av R1, R2, R3 och R4 oberoende av varandra är en halogen-, alkyl-, med 1-4 kolato-mer, eller en alkoxigrupp, med 1-4 kolatomer, eller (ii) nägon av R1, R2, R3 och R4 är en -NHR5-grupp och de kvarvarande R1, R2, R3 och R4 är väte;
29. Förening enligt patentkrav 28, vari var och en av R1, R2, R3 och R4 oberoende av varandra är en ;***; halogen-, alkylgrupp, med 1-4 kolatomer, eller en ··· >- • . alkoxigrupp, med 1-4 kolatomer; och R är väte, en ] 30 metyl- etyl-, propyl- eller bensylgrupp.
* * 30. Förening enligt patentkrav 28, vari nägon l av R1, R2, R3 och R4 är en -NH2-grupp, de kvarvarande .···. R1, R2, R3 och R4 är väte, och R6 är väte, en metyl-, • · etyl-, propyl- eller bensylgrupp.
31. Förening enligt patentkrav 28, väri den ena av X och Y är C=0 och den andra av X och Y är CH2.
32. Förening enligt patentkrav 28, vari den ena av X eller Y är C=0 och den andra av X och Y är
33. Förening enligt patentkrav 28, vari den ena av X och Y är C=0; nägon av R1, R2, R3 och R4 är en -NH2-grupp och de kvarvarande R1, R2, R3 och R4 är väte; 10 och R6 är väte.
34. Förening enligt patentkrav 28, vari fore-ningen är l-oxo-2-(2,6-dioxopiperidin-3-yl)-4-amino-isoindolin.
35. Förening enligt patentkrav 28, vari före-15 ningen är l-oxo-2-(2,6-dioxopiperidin-3-yl)-5-amino- isoindolin, l-oxo-2-(2,6-dioxopiperidin-3-yl)-6-amino- isoindolin, l-oxo-2-(2,6-dioxopiperidin-3-yl)-7-amino- isoindolin, 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-5- aminoisoindolin, 1,3-dioxo-2-(2,6-dioxopiperidin-3- 20 yl)-6-aminoisoindolin, 1,3-dioxo-2-(2,6-dioxopiperi- din-3-yl)-7-aminoisoindolin, l-oxo-2-(2,6-dioxopiperi- ....: din-3-yl)-4,5, 6, 7-tetrafluorisoindolin, l-oxo-2-(2,6- • · dioxopiperidin-3-yl)-4,5,6,7-tetraklorisoindolin, 1- • · ***. oxo-2- (2, 6-dioxopiperidin-3-yl) -4,5, 6, 7-tetraraetyliso- ····« 25 indolin, l-oxo-2-(2,6-dioxopiperidin-3-yl)-4,5,6, 7- ♦ · tetrametoxiisoindolin, 3-(l-oxo-4—aminoisoindolin-1- • · · ·.· * yl) -3-metylpiperidin-2, 6-dion, 3- (l-oxo-4— aminoiso- ··· Σ indolin-l-yl)-3-etylpiperidin-2,6-dion, 3-(l-oxo-4— aminoisoindolin-l-yl)-3-propylpiperidin-2,6-dion eller •*j*. 30 3-(3-aminoftalimido)-3-metylpiperidin-2,6-dion.
.···. 36. Förening enligt patentkrav 28, vari X och • · ”* Y är C=0.
* * 37. Förening enligt patentkrav 28, vari fore- ningen är 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4- . .·. 35 aminoisoindolin. • · ·
38. Förening enligt patentkrav 28, vari sjuk- • · domen är chocklunga, astma, autoimmun sjukdom, kakexi, en kronisk lunginflamination, kongestiv hjärtinsuffici-ens, Chrons sjukdom, endotoxisk chock, ENL vid lepra, sjukdom förorsakad av fibros, transplantat avstötning, hemodynamisk chock, skada som hänför sig tili en syre-5 rik lungbläsa, inflammation, malaria, meningit, multi- pel skleros, mykobakteriell infektion, onkogent eller cancertillständ, opportunistiskt infektion vid AIDS, osteoartrit, post-ischemisk äterflödes skada, psoriasis, stralningsskada, reumatoid artrit, reumatoid 10 spondylit, septisk chock, sepsis, sepsis syndrom, SLE eller ulcerös kölit.
39. Förening enligt patentkrav 28, väri före-ningen är en optisk isomer av föreningen enligt formel (I) . 15
40. Förening enligt patentkrav 28, väri före- ningens optiska renhet är > 95 %.
41. Förening enligt patentkrav 40, väri föreningen är (R)-l-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin eller (S)-l-oxo-2-(2,6-dioxopiperidin- 20 3-yl)-4-aminoisoindolin.
42. Förening enligt patentkrav 40, väri före- ....: ningen är (R)-1,3-dioxo-2-(2, 6-dioxopipeidin-3-yl)-4- • · ... aminoisoindolin eller (S)-1,3-dioxo-2-(2,6-dioxopipe- • · ·**. ridin-3-yl) -4-aminoisoindolin. 25 • ·· • · • · ··· ··· • · · • · · ··· • · · • · · ··· • · · • · · ··· • · • · • · · • · • · • · · • · · ··· ··· • · • · ···
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69025896 | 1996-07-24 | ||
US08690258 US5635517B1 (en) | 1996-07-24 | 1996-07-24 | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US70149496 | 1996-08-22 | ||
US08/701,494 US5798368A (en) | 1996-08-22 | 1996-08-22 | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
US4827897P | 1997-05-30 | 1997-05-30 | |
US4827897 | 1997-05-30 | ||
PCT/US1997/013375 WO1998003502A1 (en) | 1996-07-24 | 1997-07-24 | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels |
US9713375 | 1997-07-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI990101A0 FI990101A0 (sv) | 1999-01-19 |
FI990101A FI990101A (sv) | 1999-03-19 |
FI120687B true FI120687B (sv) | 2010-01-29 |
Family
ID=27367302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI990101A FI120687B (sv) | 1996-07-24 | 1999-01-19 | Substituerade 2-(2,6-dioxopiperidin-3-yl) ftalimider och -1-oxoisoindoliner samt förfarande för sänkande av TNFalfa nivåerna |
Country Status (22)
Country | Link |
---|---|
EP (4) | EP1285916B1 (sv) |
JP (1) | JP4065567B2 (sv) |
KR (2) | KR20050032629A (sv) |
CN (1) | CN1117089C (sv) |
AT (4) | ATE460409T1 (sv) |
CA (3) | CA2261762C (sv) |
CZ (3) | CZ295762B6 (sv) |
DE (4) | DE69739802D1 (sv) |
DK (2) | DK0925294T6 (sv) |
ES (4) | ES2187805T7 (sv) |
FI (1) | FI120687B (sv) |
FR (1) | FR07C0056I2 (sv) |
HK (5) | HK1050893A1 (sv) |
HU (1) | HUS1300056I1 (sv) |
LU (1) | LU91359I2 (sv) |
NL (1) | NL300291I2 (sv) |
NZ (1) | NZ333903A (sv) |
PL (2) | PL191566B1 (sv) |
PT (4) | PT925294E (sv) |
SK (1) | SK9199A3 (sv) |
UA (1) | UA60308C2 (sv) |
WO (1) | WO1998003502A1 (sv) |
Families Citing this family (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
JP4065567B2 (ja) * | 1996-07-24 | 2008-03-26 | セルジーン コーポレイション | 置換2―(2,6―ジオキソピペリジン―3―イル)フタルイミド類及び―1―オキソイソインドリン類ならびにTNFαレベルの減少方法 |
DE19703763C1 (de) * | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
ES2262753T3 (es) * | 1997-11-18 | 2006-12-01 | Celgene Corporation | 2-(2.6-dioxo-3-fluorpiperidin-3-il)-isoindolinas substituidas y su empleo para reducir los niveles de tnfalfa. |
TR200101501T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı. |
KR100672892B1 (ko) | 1999-03-18 | 2007-01-23 | 셀진 코오퍼레이션 | 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용 |
DE19917195B4 (de) * | 1999-04-16 | 2006-09-28 | Immatics Biotechnologies Gmbh | Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor |
US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
EP1353672B1 (en) * | 2000-11-30 | 2007-10-03 | The Children's Medical Center Corporation | Synthesis of 4-amino-thalidomide enantiomers |
AU2002221096A1 (en) * | 2000-12-11 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions improved in solublity in water |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7320991B2 (en) | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
DE60231989D1 (de) * | 2001-08-06 | 2009-05-28 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
CA2672000C (en) | 2002-05-17 | 2011-11-29 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404717B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
FR2845994B1 (fr) * | 2002-10-18 | 2006-05-19 | Servier Lab | Nouveaux derives de benzo[e][1,4]oxazino[3,2-g]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN1326522C (zh) * | 2002-10-24 | 2007-07-18 | 细胞基因公司 | 用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物 |
KR20050061586A (ko) * | 2002-10-31 | 2005-06-22 | 셀진 코포레이션 | 황반 변성의 치료를 위한 조성물 |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
CH696542A5 (de) * | 2003-07-09 | 2007-07-31 | Siegfried Ltd | Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen. |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CA2538864C (en) | 2003-09-17 | 2013-05-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
US7612096B2 (en) | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
CN1956718A (zh) | 2004-03-22 | 2007-05-02 | 细胞基因公司 | 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法 |
JP2007536223A (ja) * | 2004-05-05 | 2007-12-13 | セルジーン・コーポレーション | 骨髄増殖性疾患の治療及び管理のための免疫調節化合物を含む組成物、及びその使用方法 |
ES2437592T3 (es) * | 2004-09-03 | 2014-01-13 | Celgene Corporation | Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas |
WO2007005972A1 (en) | 2005-06-30 | 2007-01-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
EP1919500A2 (en) | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
ES2434946T3 (es) | 2005-08-31 | 2013-12-18 | Celgene Corporation | Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo |
JP2009507030A (ja) | 2005-09-01 | 2009-02-19 | セルジーン・コーポレーション | ワクチン及び抗感染症療法のための免疫調節性化合物の免疫学的使用 |
US20070066512A1 (en) | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物 |
CN101374941A (zh) | 2005-12-29 | 2009-02-25 | 人类起源公司 | 采集和保存胎盘干细胞的改良组合物及其使用方法 |
CA2646316C (en) | 2006-03-15 | 2016-05-24 | Theralogics, Inc. | Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
WO2007136640A2 (en) * | 2006-05-16 | 2007-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
WO2008021391A1 (en) | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
MX2009001989A (es) * | 2006-08-30 | 2009-03-09 | Celgene Corp | Compuestos de isoindolina 5-substituidos. |
PT2428513T (pt) | 2006-09-26 | 2017-08-28 | Celgene Corp | Derivados de quinazolinona substituídos em 5 como agentes anticancro |
EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
CN104623642A (zh) | 2006-10-06 | 2015-05-20 | 人类起源公司 | 天然(端肽)胎盘胶原组合物 |
WO2009042177A1 (en) | 2007-09-26 | 2009-04-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
CA3018281C (en) | 2007-09-28 | 2022-02-22 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
US20090088393A1 (en) * | 2007-09-28 | 2009-04-02 | Zomanex, Llc | Methods and formulations for converting intravenous and injectable drugs into oral dosage forms |
EP2219627A2 (en) * | 2007-11-08 | 2010-08-25 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction |
US7964354B2 (en) | 2007-12-20 | 2011-06-21 | Celgene Corporation | Use of micro-RNA as a biomarker of immunomodulatory drug activity |
EP2262768A4 (en) * | 2008-03-11 | 2011-03-23 | Reddys Lab Ltd Dr | PREPARATION OF LENALIDOMIDE |
US20110060010A1 (en) * | 2008-03-13 | 2011-03-10 | Tianjin Hemay Bio-Tech Co., Ltd | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof |
WO2009111948A1 (zh) * | 2008-03-13 | 2009-09-17 | 天津和美生物技术有限公司 | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 |
WO2009139880A1 (en) * | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
KR20180000750A (ko) | 2008-10-29 | 2018-01-03 | 셀진 코포레이션 | 암의 치료에 사용하기 위한 이소인돌린 화합물 |
DE102008057335A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | Amorphes Lenalidomid |
WO2010056344A1 (en) * | 2008-11-14 | 2010-05-20 | Concert Pharmaceuticals Inc. | Substituted dioxopiperidinyl phthalimide derivaties |
DE102008057285A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung |
US9045453B2 (en) | 2008-11-14 | 2015-06-02 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
DE102008057284A1 (de) | 2008-11-14 | 2010-05-20 | Ratiopharm Gmbh | Tabletten enthaltend Lenalidomid und Adhäsionsverstärker |
US20120053159A1 (en) | 2009-02-11 | 2012-03-01 | Muller George W | Isotopologues of lenalidomide |
CA3110964A1 (en) | 2009-03-25 | 2010-09-30 | Xiaokui Zhang | Preventing a symptom of graft-versus-host disease using human placenta-derived intermediate natural killer cells |
EP3199149A1 (en) | 2009-05-19 | 2017-08-02 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
CN101580501B (zh) | 2009-06-01 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体 |
AU2010290822A1 (en) | 2009-09-03 | 2012-03-29 | Ranbaxy Laboratories Limited | Process for the preparation of lenalidomide |
WO2011050962A1 (en) * | 2009-10-29 | 2011-05-05 | Ratiopharm Gmbh | Acid addition salts of lenalidomide |
CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN102127054B (zh) * | 2009-11-02 | 2013-04-03 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
WO2011069608A1 (en) * | 2009-12-09 | 2011-06-16 | Ratiopharm Gmbh | S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide |
RU2012131164A (ru) | 2009-12-22 | 2014-01-27 | Селджин Корпорейшн | (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение |
MX337566B (es) | 2010-01-05 | 2016-03-10 | Celgene Corp | Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. |
EP3599236B1 (en) | 2010-02-11 | 2023-08-23 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
CA2794096A1 (en) | 2010-04-07 | 2011-10-13 | Celgene Corporation | Methods for treating respiratory viral infection |
WO2012078492A1 (en) | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
JP6132773B2 (ja) | 2011-01-10 | 2017-05-24 | セルジーン コーポレイション | Pde4及び/又はサイトカインの阻害剤としてのフェネチルスルホンイソインドリン誘導体 |
ES2656855T3 (es) | 2011-03-11 | 2018-02-28 | Celgene Corporation | Formas sólidas de 3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidina-2,6-diona y sus composiciones farmacéuticas y usos |
AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
WO2012145309A1 (en) | 2011-04-18 | 2012-10-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
EP3096142A3 (en) | 2011-04-29 | 2017-03-08 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
ES2803524T3 (es) | 2011-09-14 | 2021-01-27 | Amgen Europe Gmbh | Formulaciones de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida del ácido ciclopropanocarboxílico |
US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
EP3756650A1 (en) | 2011-12-27 | 2020-12-30 | Amgen (Europe) GmbH | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
WO2013126394A1 (en) * | 2012-02-21 | 2013-08-29 | Celgene Corporation | Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
EP2858667A1 (en) | 2012-06-06 | 2015-04-15 | Bionor Immuno AS | Hiv vaccine |
JP6318152B2 (ja) | 2012-06-29 | 2018-04-25 | セルジーン コーポレイション | セレブロン関連タンパク質を利用して薬物効能を決定する方法 |
CA2878954C (en) | 2012-08-09 | 2020-12-08 | Benjamin M. Cohen | Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
US9643950B2 (en) | 2012-10-22 | 2017-05-09 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
FR2999914B1 (fr) * | 2012-12-21 | 2015-08-07 | Oreal | Utilisation de derives de l'acide imidocarboxylique pour traiter les alterations de la peau liees a l'age ou au photovieillissement |
FR2999915B1 (fr) * | 2012-12-21 | 2017-08-11 | Oreal | Utilisation de derives de l'acide imidocarboxylique en tant qu'agent apaisant |
WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
JP2016506968A (ja) | 2013-02-05 | 2016-03-07 | アントフロゲネシス コーポレーション | 胎盤由来のナチュラルキラー細胞 |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
WO2014152177A1 (en) | 2013-03-15 | 2014-09-25 | Anthrogenesis Corporation | Modified t lymphocytes |
CN104072476B (zh) * | 2013-03-27 | 2018-08-21 | 江苏豪森药业集团有限公司 | 泊马度胺晶型及其制备方法和用途 |
EP2986318A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
CN103497174B (zh) * | 2013-07-29 | 2015-10-28 | 杭州派臣医药科技有限公司 | 泊利度胺的制备和精制方法 |
CN104557857A (zh) * | 2013-10-29 | 2015-04-29 | 上海医药工业研究院 | 一种泊利度胺的纯化方法 |
CN104557858B (zh) * | 2013-10-29 | 2018-06-01 | 上海医药工业研究院 | 一种泊利度胺的制备方法 |
EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
CN104016967A (zh) * | 2014-04-04 | 2014-09-03 | 南京工业大学 | 一种泊利度胺的合成方法 |
CN106458993A (zh) * | 2014-04-14 | 2017-02-22 | 阿尔维纳斯股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
EP3160486B1 (en) | 2014-06-27 | 2020-11-18 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
CN105348257A (zh) * | 2014-08-20 | 2016-02-24 | 河北菲尼斯生物技术有限公司 | 泊马度胺的制备方法 |
BR112017003620A2 (pt) | 2014-08-22 | 2017-12-05 | Celgene Corp | métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos |
CN105440013B (zh) * | 2014-08-29 | 2018-10-09 | 杭州和泽医药科技有限公司 | 一种泊马度胺的制备方法 |
AU2015341301B2 (en) * | 2014-10-30 | 2019-05-16 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
EP3233082B1 (en) | 2014-12-19 | 2018-12-05 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
US10507204B2 (en) | 2014-12-19 | 2019-12-17 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
CN104447689B (zh) * | 2014-12-22 | 2016-07-20 | 上海迈柏医药科技有限公司 | 来那度胺的晶型及其制备方法 |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
AU2016209349B2 (en) | 2015-01-20 | 2020-05-07 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the Androgen Receptor |
CN107787320B (zh) | 2015-05-22 | 2020-12-04 | 拜欧赛里克斯公司 | 靶向蛋白质的化合物、其组合物、方法和用途 |
US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
HUE065109T2 (hu) | 2015-06-26 | 2024-05-28 | Celgene Corp | Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása |
US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
MX2018007704A (es) | 2015-12-22 | 2018-11-09 | Synthon Bv | Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
EP3526202A4 (en) | 2016-10-11 | 2020-04-29 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR |
CA3042260C (en) | 2016-11-01 | 2023-10-03 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
CN111454248A (zh) | 2016-12-01 | 2020-07-28 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
CA3045508A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
EP3527210B1 (en) | 2016-12-16 | 2021-06-09 | Kangpu Biopharmaceuticals, Ltd. | Combined composition comprising a benzoheterocyclic compound and an androgen receptor pathway modulator and uses thereof |
CN110741004B (zh) | 2016-12-23 | 2023-10-17 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
EP3559002A4 (en) | 2016-12-23 | 2021-02-17 | Arvinas Operations, Inc. | CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
AU2018211975B2 (en) | 2017-01-26 | 2022-05-26 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
US20200000776A1 (en) | 2017-02-13 | 2020-01-02 | Kangpu Biopharmaceuticals, Ltd. | Combination treating prostate cancer, pharmaceutical composition and treatment method |
CN111182909A (zh) | 2017-05-01 | 2020-05-19 | 朱诺治疗学股份有限公司 | 细胞疗法与免疫调节化合物的组合 |
US10093647B1 (en) | 2017-05-26 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof |
CA3065120A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
EP3644721A1 (en) | 2017-06-29 | 2020-05-06 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
US10093649B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof |
US10093648B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
WO2019067792A1 (en) | 2017-09-28 | 2019-04-04 | Celularity, Inc. | TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY |
US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
CN111511370A (zh) | 2017-11-01 | 2020-08-07 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体 |
WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
EP3724225A1 (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
EP3505158A1 (en) | 2017-12-27 | 2019-07-03 | KRKA, d.d., Novo mesto | Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt |
US11452722B2 (en) | 2018-01-11 | 2022-09-27 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE BASED MODULATORS OF PROTEOLYSIS AND METHOD OF USE |
EP3755718A1 (en) | 2018-02-21 | 2020-12-30 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
EP3545949A1 (en) | 2018-03-29 | 2019-10-02 | Midas Pharma GmbH | Oral dosage forms comprising pomalidomide crystalline form a |
MX2020010420A (es) | 2018-04-04 | 2020-12-11 | Arvinas Operations Inc | Moduladores de la proteólisis y métodos asociados de uso. |
WO2019199134A1 (ko) | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드를 포함하는 약제학적 조성물 |
JP2021518424A (ja) | 2018-04-13 | 2021-08-02 | サムヤン バイオファーマシューティカルズ コーポレイションSamyang Biopharmaceuticals Corporation | 様々な用量のレナリドミドの経口用錠剤組成物 |
WO2019199133A1 (ko) | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드의 경구용 코팅 정제 조성물 |
KR102286500B1 (ko) | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 레날리도마이드를 포함하는 경구용 고형제제의 제조방법 |
KR102259798B1 (ko) | 2018-04-13 | 2021-06-02 | 주식회사 삼양홀딩스 | 붕해가 개선된 레날리도마이드의 경구용 정제 조성물 |
CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
EP3876958A1 (en) | 2018-11-08 | 2021-09-15 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
SG11202105084VA (en) | 2018-11-16 | 2021-06-29 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
PT3886875T (pt) | 2018-11-30 | 2024-06-27 | Juno Therapeutics Inc | Métodos para tratamento utilizando terapia celular adotiva |
WO2020118098A1 (en) * | 2018-12-05 | 2020-06-11 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
MA54863A (fr) | 2019-01-29 | 2021-12-08 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1) |
US20230248696A1 (en) * | 2019-05-03 | 2023-08-10 | Dynamic Biologics Inc. | Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma |
CN110343063A (zh) * | 2019-08-09 | 2019-10-18 | 新乡双鹭药业有限公司 | 一种泊马度胺合成中杂质的制备方法 |
WO2021061644A1 (en) * | 2019-09-23 | 2021-04-01 | Accutar Biotechnology Inc. | Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof |
EP4034114A4 (en) * | 2019-09-23 | 2023-07-26 | Accutar Biotechnology Inc. | NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES |
US11548870B2 (en) | 2019-11-19 | 2023-01-10 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of helios protein |
KR20220119094A (ko) | 2019-12-19 | 2022-08-26 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법 |
MX2022012964A (es) | 2020-04-15 | 2022-11-09 | Tecnimede Soc Tecnico Medicinal Sa | Forma de dosificacion oral solida que comprende pomalidomida. |
US12043612B2 (en) | 2020-05-09 | 2024-07-23 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
TW202304881A (zh) | 2021-04-06 | 2023-02-01 | 美商必治妥美雅史谷比公司 | 經吡啶基取代之側氧基異吲哚啉化合物 |
AU2022259683A1 (en) | 2021-04-16 | 2023-10-19 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
WO2023126531A1 (en) | 2021-12-31 | 2023-07-06 | A Fine House S.A. | Lenalidomide oral solution |
WO2023126530A1 (en) | 2021-12-31 | 2023-07-06 | A Fine House S.A. | Oral solution comprising lenalidomide |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
DE4422237A1 (de) * | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
JP4065567B2 (ja) * | 1996-07-24 | 2008-03-26 | セルジーン コーポレイション | 置換2―(2,6―ジオキソピペリジン―3―イル)フタルイミド類及び―1―オキソイソインドリン類ならびにTNFαレベルの減少方法 |
-
1997
- 1997-07-24 JP JP50725998A patent/JP4065567B2/ja not_active Expired - Lifetime
- 1997-07-24 PT PT97936295T patent/PT925294E/pt unknown
- 1997-07-24 DE DE69739802T patent/DE69739802D1/de not_active Expired - Lifetime
- 1997-07-24 CN CN97180299A patent/CN1117089C/zh not_active Ceased
- 1997-07-24 AT AT02012942T patent/ATE460409T1/de active
- 1997-07-24 KR KR1020057004561A patent/KR20050032629A/ko not_active Application Discontinuation
- 1997-07-24 SK SK91-99A patent/SK9199A3/sk unknown
- 1997-07-24 PT PT10152833T patent/PT2177517E/pt unknown
- 1997-07-24 EP EP20020012942 patent/EP1285916B1/en not_active Expired - Lifetime
- 1997-07-24 DE DE69717831.5T patent/DE69717831T3/de not_active Expired - Lifetime
- 1997-07-24 KR KR10-1999-7000565A patent/KR100534498B1/ko not_active IP Right Cessation
- 1997-07-24 PT PT09151443T patent/PT2070920E/pt unknown
- 1997-07-24 AT AT09151443T patent/ATE500240T1/de active
- 1997-07-24 CZ CZ1999202A patent/CZ295762B6/cs not_active IP Right Cessation
- 1997-07-24 ES ES97936295.1T patent/ES2187805T7/es active Active
- 1997-07-24 PT PT02012942T patent/PT1285916E/pt unknown
- 1997-07-24 DK DK97936295.1T patent/DK0925294T6/da active
- 1997-07-24 AT AT10152833T patent/ATE530542T1/de active
- 1997-07-24 PL PL332867A patent/PL191566B1/pl unknown
- 1997-07-24 EP EP20100183268 patent/EP2305663B1/en not_active Expired - Lifetime
- 1997-07-24 ES ES10152833T patent/ES2372577T3/es not_active Expired - Lifetime
- 1997-07-24 ES ES10183268.1T patent/ES2529190T3/es not_active Expired - Lifetime
- 1997-07-24 EP EP20090151443 patent/EP2070920B8/en not_active Expired - Lifetime
- 1997-07-24 CA CA 2261762 patent/CA2261762C/en not_active Expired - Lifetime
- 1997-07-24 DK DK02012942T patent/DK1285916T3/da active
- 1997-07-24 WO PCT/US1997/013375 patent/WO1998003502A1/en active Application Filing
- 1997-07-24 CA CA 2560523 patent/CA2560523C/en not_active Expired - Lifetime
- 1997-07-24 CA CA 2624949 patent/CA2624949C/en not_active Expired - Lifetime
- 1997-07-24 CZ CZ20050108A patent/CZ302378B6/cs not_active IP Right Cessation
- 1997-07-24 PL PL97373743A patent/PL195916B1/pl unknown
- 1997-07-24 DE DE69740140T patent/DE69740140D1/de not_active Expired - Lifetime
- 1997-07-24 DE DE200712000079 patent/DE122007000079I2/de active Active
- 1997-07-24 CZ CZ2011-89A patent/CZ304569B6/cs not_active IP Right Cessation
- 1997-07-24 ES ES02012942T patent/ES2339425T3/es not_active Expired - Lifetime
- 1997-07-24 UA UA99010371A patent/UA60308C2/uk unknown
- 1997-07-24 EP EP97936295.1A patent/EP0925294B3/en not_active Expired - Lifetime
- 1997-07-24 NZ NZ333903A patent/NZ333903A/en not_active IP Right Cessation
- 1997-07-24 AT AT97936295T patent/ATE229521T3/de unknown
-
1999
- 1999-01-19 FI FI990101A patent/FI120687B/sv not_active IP Right Cessation
- 1999-12-24 HK HK03103021A patent/HK1050893A1/xx not_active IP Right Cessation
- 1999-12-24 HK HK99106117A patent/HK1021819A1/xx not_active IP Right Cessation
- 1999-12-24 HK HK10109800A patent/HK1143360A1/xx not_active IP Right Cessation
-
2007
- 2007-09-06 LU LU91359C patent/LU91359I2/fr unknown
- 2007-09-10 NL NL300291C patent/NL300291I2/nl unknown
- 2007-11-05 FR FR07C0056C patent/FR07C0056I2/fr active Active
-
2009
- 2009-12-11 HK HK09111701A patent/HK1132502A1/xx not_active IP Right Cessation
-
2011
- 2011-07-26 HK HK11107802.0A patent/HK1153736A1/xx not_active IP Right Cessation
-
2013
- 2013-10-15 HU HUS1300056C patent/HUS1300056I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI120687B (sv) | Substituerade 2-(2,6-dioxopiperidin-3-yl) ftalimider och -1-oxoisoindoliner samt förfarande för sänkande av TNFalfa nivåerna | |
US6555554B2 (en) | Isoindolines, method of use, and pharmaceutical compositions | |
US6316471B1 (en) | Isoindolines, method of use, and pharmaceutical compositions | |
US8288415B2 (en) | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione | |
NO331367B1 (no) | 1-okso-2-(2,6 dioksopiperidin-3-yl)-4-aminoisoindolin samt farmasoytisk sammensetning inneholdende en slik forbindelse | |
JP2015131863A (ja) | 置換2−(2,6−ジオキソピペリジン−3−イル)フタルイミド類及び−1−オキソイソインドリン類ならびにTNFαレベルの減少方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 120687 Country of ref document: FI |
|
MA | Patent expired |